Biological Pathway‐Based Genome‐Wide Association Analysis Identified the Vasoactive Intestinal Peptide (VIP) Pathway Important for Obesity

Recent genome‐wide association (GWA) studies have identified a number of novel genes/variants predisposing to obesity. However, most GWA studies have focused on individual single‐nucleotide polymorphism (SNPs)/genes with a strong statistical association with a phenotypic trait without considering potential biological interplay of the tested genes. In this study, we performed biological pathway‐based GWA analysis for BMI and body fat mass. We used individual level genotype data generated from 1,000 unrelated US whites that were genotyped for ∼500,000 SNPs. Statistical analysis of pathways was performed using a modification of the Gene Set Enrichment Algorithm. A total of 963 pathways extracted from the BioCarta, Kyoto Encyclopedia of Genes and Genomes (KEGG), Ambion GeneAssist, and Gene Ontology (GO) databases were analyzed. Among all of the pathways analyzed, the vasoactive intestinal peptide (VIP) pathway was most strongly associated with fat mass (nominal P = 0.0009) and was the third most strongly associated pathway with BMI (nominal P = 0.0006). After multiple testing correction, the VIP pathway achieved false‐discovery rate (FDR) q values of 0.042 and 0.120 for fat mass and BMI, respectively. Our study is the first to demonstrate that the VIP pathway may play an important role in development of obesity. The study also highlights the importance of pathway‐based GWA analysis in identification of additional genes/variants for complex human diseases.

[1]  M. Furuse,et al.  Pituitary adenylate cyclase activating polypeptide and vasoactive intestinal peptide inhibit feeding in the chick brain by different mechanisms , 2003, Neuroscience Letters.

[2]  K. Lange,et al.  Prioritizing GWAS results: A review of statistical methods and recommendations for their application. , 2010, American journal of human genetics.

[3]  Jing Huang,et al.  Dynamic model based algorithms for screening and genotyping over 100K SNPs on oligonucleotide microarrays , 2005, Bioinform..

[4]  Philippe Froguel,et al.  The genetic contribution to non-syndromic human obesity , 2009, Nature Reviews Genetics.

[5]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[6]  Philippe Froguel,et al.  Genome-wide association scans identified CTNNBL1 as a novel gene for obesity. , 2008, Human molecular genetics.

[7]  D. Maraganore,et al.  A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson Disease , 2007, PLoS genetics.

[8]  Kai Wang,et al.  Pathway-based approaches for analysis of genomewide association studies. , 2007, American journal of human genetics.

[9]  G. Makhlouf,et al.  Stimulation of insulin and glucagon secretion by vasoactive intestinal peptide. , 1977, The American journal of physiology.

[10]  Claude Bouchard,et al.  Handbook of obesity , 1997 .

[11]  S. Shioda,et al.  Inhibitory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus , 2005, Peptides.

[12]  B. Ahrén,et al.  Role of VIP and PACAP in islet function , 2007, Peptides.

[13]  Steven J. Schrodi,et al.  Neither Replication nor Simulation Supports a Role for the Axon Guidance Pathway in the Genetics of Parkinson's Disease , 2008, PloS one.

[14]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Rostène,et al.  A new neuroregulator: The vasoactive intestinal peptide or VIP , 1982, Molecular and Cellular Endocrinology.

[16]  K. Maruyama,et al.  Regulation of feeding behavior by pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) in vertebrates , 2007, Peptides.

[17]  Joseph S. Takahashi,et al.  The Meter of Metabolism , 2008, Cell.

[18]  H. Hsiung,et al.  Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. , 2002, Endocrinology.

[19]  Erik D Herzog,et al.  Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons , 2005, Nature Neuroscience.

[20]  Terence P. Speed,et al.  Genome analysis A genotype calling algorithm for affymetrix SNP arrays , 2005 .

[21]  C. Wijmenga,et al.  Using genome‐wide pathway analysis to unravel the etiology of complex diseases , 2009, Genetic epidemiology.

[22]  S. Shioda,et al.  Effects of Pituitary Adenylate Cyclase‐Activating Polypeptide and Vasoactive Intestinal Polypeptide on Food Intake and Locomotor Activity in the Goldfish, Carassius auratus , 2006, Annals of the New York Academy of Sciences.

[23]  J. Bockaert,et al.  PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. , 2000, The Journal of clinical investigation.

[24]  S. Seino,et al.  PACAP/VIP Receptors in Pancreatic β‐Cells: Their Roles in Insulin Secretion a , 1996 .

[25]  P. Xiao,et al.  Searching for obesity genes: progress and prospects. , 2005, Drugs of Today.

[26]  E. González-Rey,et al.  Role of vasoactive intestinal peptide in inflammation and autoimmunity. , 2005, Current opinion in investigational drugs.

[27]  M. Horowitz,et al.  Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice , 1992, Peptides.